Factors that affect how well mesenchymal stromal cell (MSC) therapy works for hepatitis B–related acute-on-chronic liver failure.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center retrospective analysis will include consecutive patients with hepatitis B–related ACLF treated with mesenchymal stromal cell (MSC) infusions at the Third Affiliated Hospital of Sun Yat-sen University between January 2010 and October 2018. Clinical data including survival status, liver function tests, and complications will be extracted from medical records. Patients with co-infections (HCV, HIV), active malignancy, marked organ dysfunction, pregnancy, primary thyroid disease, or incomplete records were excluded. Statistical analyses will identify clinical and demographic risk factors associated with whether patients derived benefit from MSC treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Clinical diagnosis of acute-on-chronic liver failure; Positive serum HBV surface antigen for more than 6 months; Received MSCs infusion more than one time.

Exclusion Criteria:

* Systemic or local malignancy; Hepatitis C virus infection; HIV infection or other immunodeficiency disease; Marked organ dysfunction (e.g., renal dysfunction); Pregnancy or lactation; Hyperthyroidism or other primary thyroid diseases; Incomplete data or lost to follow-up; Hospital stay \< 1 day.

Where it's running

• Third Affiliated Hospital of Sun Yat-sen University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Dr. Chen
• Email: chenjf36@mail.sysu.edu.cn
• Phone: +86-20-85252081

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AS1501 in ACLF: a two-stage dose study in adults with acute-on-chronic liver failure

  This Phase II study tests AS1501 given by injection in adults with early ACLF to see if it’s safe and tolerable and to guide dosing.

  Recruiting Phase 2 Shenzhen Third People's Hospital · Shenzhen, Guangdong · NCT06916585

• TAK-242 and G-CSF in ACLF: a new treatment approach for adults with acute-on-chronic liver failure

  This trial tests whether adding TAK-242, with or without G-CSF, to standard ACLF care helps patients with severe alcoholic hepatitis and ACLF.

  Recruiting Phase 2 Yaqrit Ltd · London, Greater London · NCT06890039

• Using different ROTEM cut-offs to guide blood transfusions before procedures in cirrhosis and ACLF

  This will test whether using relaxed ROTEM cut-offs to decide on blood transfusions reduces the number of transfusions without raising bleeding risk for people with cirrhosis or ACLF and severe coagulopathy who need invasive procedures.

  Recruiting Institute of Liver and Biliary Sciences, India · New Delhi, National Capital Territory of Delhi · NCT06831565

• Ceftazidime-avibactam vs high-dose meropenem for ACLF patients with hospital-acquired infections

  This trial tests whether ceftazidime-avibactam can better treat infections in ACLF patients than high-dose meropenem given in extended infusions, aiming to spare carbapenems if possible.

  Recruiting Institute of Liver and Biliary Sciences, India · New Delhi, National Capital Territory of Delhi · NCT06818565

• Evaluating a new treatment for liver failure and sepsis

  This study is testing a new treatment for people with liver failure and sepsis to see if it can help them survive and improve their organ function.

  Recruiting Third Affiliated Hospital, Sun Yat-Sen University · Guangzhou, Guangdong · NCT06562803

• Using CytoSorb device for patients with acute on chronic liver failure

  This study tests if using the CytoSorb device can help lower bilirubin and ammonia levels and improve muscle strength in patients with severe liver failure.

  Recruiting University Hospital, Antwerp · Edegem, Antwerp · NCT06079021

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.